Displaying drugs 11026 - 11050 of 11910 in total
Dendritic cells vaccine
The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the recombinant chimeric DC vaccine reduces the risk of virulence recovery, pre-existing anti-vector immunity, and incomplete viral inactivation.
As...
Investigational
Matched Description: … The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and ... With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the …
VP025
VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation. VP025 may inhibit immune system activation and protect motoneurons from injury. It also shows the ability to reduce inflammation across the blood-brain barrier and improve correlates of memory and learning function. It is being developed to...
Investigational
Matched Description: … It is considered to be a systemic anti-inflammatory and neuroprotective agent. ... VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol ... developed to target the chronic inflammation within the central nervous system that is associated with a …
(R)-Rolipram
The (R)-enantiomer of rolipram, it is a phosphodiesterase inhibitor with antidepressant properties.
Experimental
Matched Description: … The (R)-enantiomer of rolipram, it is a phosphodiesterase inhibitor with antidepressant properties. …
Guanosine-5'-Diphosphate
A guanine nucleotide containing two phosphate groups esterified to the sugar moiety. [PubChem]
Experimental
Matched Description: … A guanine nucleotide containing two phosphate groups esterified to the sugar moiety. [PubChem] …
Zaltoprofen
A non-steroidal anti-inflammatory drug approved for use in Japan in 1993.
Experimental
Matched Description: … A non-steroidal anti-inflammatory drug approved for use in Japan in 1993. …
Landiolol
Landiolol is a rapid-acting beta-blocker used for rapid ventricular rate control.
Investigational
Matched Description: … Landiolol is a rapid-acting beta-blocker used for rapid ventricular rate control. …
KDT-3594
KDT-3594 is a non-ergot dopamine receptor agonist developed by Kissei Pharmaceutical.
Investigational
Matched Description: … KDT-3594 is a non-ergot dopamine receptor agonist developed by Kissei Pharmaceutical. …
TASO-001
TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.
Investigational
Matched Description: … TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide. …
LYT-200
LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
Investigational
Matched Description: … LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9. …
HMI-204
HMI-204 is an adeno-associated virus serotype HSC15 expressing human arylsulfatase A
Investigational
Matched Description: … HMI-204 is an adeno-associated virus serotype HSC15 expressing human arylsulfatase A …
XTMAB-16
XTMAB-16 is a monoclonal antibody directed against tumour necrosis factor-alpha (TNFα).
Investigational
Matched Description: … XTMAB-16 is a monoclonal antibody directed against tumour necrosis factor-alpha (TNFα). …
Varespladib methyl
Varespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.
Investigational
Fasinumab
Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). It is currently under investigation for the treatment osteoarthritic pain and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e. NSAIDs and/or opioids) in this patient population. NGF was first discovered...
Investigational
Matched Description: … Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). …
BOS172722
BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential anticancer agent. Normally, Mps1 supports the proper division of cancer cells, ensuring survival and replication. The key role of Mps1 in the growth of cancer cells renders it an appealing target for cancer treatment,...
Experimental
Matched Description: … BOS172722 is a novel and selective Monopolar spindle 1 (Mps1) kinase inhibitor identified as a potential …
2'-Deoxycytidine-5'-Monophosphate
Deoxycytidine (dihydrogen phosphate). A deoxycytosine nucleotide containing one phosphate group esterified to the deoxyribose moiety in the 2'-,3'- or 5- positions. [PubChem]
Experimental
Matched Description: … A deoxycytosine nucleotide containing one phosphate group esterified to the deoxyribose moiety in the …
Bifeprunox
Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.
Investigational
Matched Description: … Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 …
L-deprenyl-D2 C-11
L-deprenyl-D2 C-11 is under investigation in clinical trial NCT01701089 (A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers).
Investigational
Matched Description: … L-deprenyl-D2 C-11 is under investigation in clinical trial NCT01701089 (A Study of RO4602522 in Patients …
Emactuzumab
Emactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).
Investigational
Matched Description: … Emactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy …
Padsevonil
Padsevonil is under investigation in clinical trial NCT03695094 (A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil).
Investigational
Matched Description: … Padsevonil is under investigation in clinical trial NCT03695094 (A Study in Participants With Epilepsy …
IONIS-HBVRx
IONIS-HBVRx is under investigation in clinical trial NCT04544956 (A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B).
Investigational
Matched Description: … IONIS-HBVRx is under investigation in clinical trial NCT04544956 (A Mechanistic Study of GSK3228836 With …
Virulizin
Investigational
DOTMP SM-153
Investigational
Putrescine
Putrescine is a toxic diamine formed by putrefaction from the decarboxylation of arginine and ornithine. Putrescine is a solid. This compound belongs to the polyamines. These are compounds containing more than one amine group. Known drug targets of putrescine include putrescine-binding periplasmic protein, ornithine decarboxylase, and S-adenosylmethionine decarboxylase proenzyme.
Experimental
Matched Description: … Putrescine is a solid. This compound belongs to the polyamines. ... Putrescine is a toxic diamine formed by putrefaction from the decarboxylation of arginine and ornithine …
4'-Methylene-5,8,10-trideazaaminopterin
CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier (RFC) system than is Methotrexate. It has been investigated for the treatment of Rheumatoid Arthritis (phase II).
Investigational
Matched Description: … CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable …
Tesaglitazar
Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.
Investigational
Matched Description: … Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves ... Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical …
Displaying drugs 11026 - 11050 of 11910 in total